Related references
Note: Only part of the references are listed.Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT
Amelie Kinch et al.
LEUKEMIA & LYMPHOMA (2018)
Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT
D. M. Burns et al.
BONE MARROW TRANSPLANTATION (2016)
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines
Jan Styczynski et al.
HAEMATOLOGICA (2016)
894895 Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy
Mihaja Raberahona et al.
TRANSPLANT INFECTIOUS DISEASE (2016)
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines
Jan Styczynski et al.
HAEMATOLOGICA (2016)
EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era
C. P. Fox et al.
BONE MARROW TRANSPLANTATION (2014)
EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT
L. Rasche et al.
BONE MARROW TRANSPLANTATION (2014)
Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation
Michael Uhlin et al.
HAEMATOLOGICA (2014)
Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus-Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
Jan Styczynski et al.
CLINICAL INFECTIOUS DISEASES (2013)
Rituximab Treatment for Epstein-Barr Virus DNAemia after Alternative-Donor Hematopoietic Stem Cell Transplantation
Stefania Coppoletta et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
Helen E. Heslop et al.
BLOOD (2010)
Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells
Andreas Moosmann et al.
BLOOD (2010)
Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation
Ben Carpenter et al.
TRANSPLANTATION (2010)
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation
Ola Landgren et al.
BLOOD (2009)
Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases
J. Styczynski et al.
TRANSPLANT INFECTIOUS DISEASE (2009)
EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning
Jonathan M. Cohen et al.
LEUKEMIA & LYMPHOMA (2007)
Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution
Nicola E. Annels et al.
CLINICAL INFECTIOUS DISEASES (2006)
Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era
IM Ghobrial et al.
LEUKEMIA & LYMPHOMA (2005)
Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation:: Relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy
E Clave et al.
TRANSPLANTATION (2004)
Epstein-Barr virus infection.
JI Cohen
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
